SETD2 and prostate carcinoma: SETD2 is strongly correlated with the presence of EZH2-K735me1 and particularly found in patients with prostate cancer with better clinical outcome.111 On the contrary, EHZ2-K307 methylation by SMYD2 improves its stability and participates in the transcriptional repression of pro-apoptotic, anti-proliferation and anti-invasion target genes112 (Fig. 3c).